Strategic Partners

BlueRock Therapeutics

BlueRock Therapeutics is a next-generation regenerative medicine company developing best-in-class induced pluripotent stem cell (iPSC) therapies to cure a range of diseases using an industry-leading platform. BlueRock was established by Bayer AG and Versant Ventures to develop breakthrough treatments based on the latest stem cell technology in combination with superior cell differentiation protocols. Once of the Company’s initial programs is to regenerate heart muscle in patients who have had a heart attack (myocard infarction, MI) or are suffering from chronic heart failure, the leading causes of morbidity and mortality worldwide.

VistaGen has entered into an exclusive sublicense agreement with BlueRock Therapeutics for rights to certain proprietary technologies relating to the production of cardiac stem cells for the treatment of heart disease. VistaGen received an upfront payment of $1.25 million and has the potential to receive additional milestone payments and royalties in the future.

Cardiac Safety Research Consortium

Cardiovascular disease is the leading cause of death in the United States, accounting for more than one quarter of all deaths every year. Some medical products intended to treat cardiovascular disease and other diseases have significant and potentially dangerous side effects related to their effects on the heart. Moreover, cardiac safety concerns are a leading cause for the recall of marketed drugs and abandonment of drug development programs for any indication. The Cardiac Safety Research Consortium (CSRC) was launched in 2006 through an FDA Critical Path Initiative Memorandum of Understanding with Duke University to support research into the evaluation of cardiac safety of medical products.

CSRC supports research by engaging stakeholders from industry, academia and government to share data and expertise. Outputs of the CSRC include research projects taking advantage of waveforms released from the FDA ECG warehouse, Think Tank Incubator programs and consensus white papers. Additional work is underway to expand the portfolio of research projects beyond the ECG data into other areas of cardiac safety evaluation from the preclinical through the post-market periods. Click here to learn more about our work with the CSRC.

The Centre for Commercialization of Regenerative Medicine

The Centre for Commercialization of Regenerative Medicine (CCRM) is a Canadian, not-for-profit organization supporting the development of foundational technologies that accelerate the commercialization of stem cell- and biomaterials-based products and therapies. CCRM is supported by the Centres of Excellence for Commercialization and Research (CECR) Program. CCRM brings together leading Regenerative Medicine (RM) experts from the University of Toronto and McMaster University, with researchers from the Hospital for Sick Children, the University Heath Network, the Ottawa Hospital Research Institute and Mount Sinai Hospital, to accelerate RM research and development, and create a commercialization pipeline that rapidly brings RM technologies to market. These researchers are working to harness the power of stem cells, biomaterials and molecules through innovative technologies to treat, and perhaps cure, diseased cells, tissues and organs.

The McEwen Centre for Regenerative Medicine

The McEwen Centre for Regenerative Medicine's mission is to be a catalyst for regenerative medicine by facilitating collaboration, supporting research and promoting awareness of the field. The Centre includes 15 scientists at five Toronto hospitals, as well as the University of Toronto. Currently, these scientists are working to accelerate the development of more effective treatments for conditions such as heart disease, diabetes, respiratory disease and spinal cord injury. The McEwen Centre is supported by philanthropic contributions and research grants, and is based at University Health Network in Toronto, Canada. They also collaborate with many other research institutions throughout North America, Europe and the Asia/Pacific region.

Icahn School of Medicine at Mount Sinai

Internationally regarded for its dedication to medical science, Mount Sinai is home to an array of leading research institutes, centers and laboratories, all of which work toward rapidly translating advances in basic science into innovative patient care. With a rich history in clinical milestones and an unequaled passion for patient-focused research, Mount Sinai has pioneered breakthroughs benefiting untold numbers of lives.

Synterys, Inc.

Synterys, Inc. is a San Francisco Bay Area medicinal chemistry and collaborative drug discovery provider focused on the needs of virtual and small drug discovery companies. They are headquartered in the U.S. with fully modern overseas facilities in Taiwan. With an internal focus on high-quality synthetic organic medicinal chemistry, they are virtually integrated with outstanding computational chemistry, DMPK and manufacturing partners to provide all the tools necessary for the rapid advancement of discovery projects. The company's highly experienced senior management team and staff have multiple years of experience in large pharmaceutical and small biotech companies and a proven track record of drug discovery success with numerous clinical candidates invented.

University Health Network

Providing care to the community for more than 200 years, University Health Network (UHN) is a major landmark in Canada's healthcare system and a teaching hospital of the University of Toronto. Building on the strengths and reputation of each of the three hospitals, Princess Margaret Hospital, Toronto General Hospital and Toronto Western Hospital, UHN brings together the talent and resources needed to achieve global impact and provide exemplary patient care, research and education. Approximately 2,700 scientists, technical staff, students and trainees at University Health Network are working together to solve fundamental and applied research problems, with much of the research focused on four priority platforms: Genes, Proteins, and People; Medical Technology Innovation; Health Informatics; and Regenerative Medicine.